Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02862574 · ClinicalTrials.gov registry record · Phase 2
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02862574 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 15 participants.
The verdict
NCT02862574, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).
Interventions
- DRUG Placebo
- DRUG Andecaliximab
- DRUG Methotrexate
- DRUG TNF Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2017-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02862574
The ClinicalTrials.gov registry entry for NCT02862574 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02862574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02862574 about?
NCT02862574 is a clinical study titled "Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis". The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).
What is the current status of trial NCT02862574?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2016-12-15. Estimated completion is 2017-08-07.
What interventions are being tested in trial NCT02862574?
The interventions under investigation include: Placebo (DRUG), Andecaliximab (DRUG), Methotrexate (DRUG), TNF Inhibitor (DRUG).
Who is sponsoring clinical trial NCT02862574?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.